Rate My Professor Rathindra Bose

Bose specialized in research at the intersection of medicine and energy, with a focus on developing less toxic platinum-based anticancer drugs and compounds for fuel cell catalysts. Over more than two decades, he investigated the mechanisms of platinum chemotherapies and discovered the phosphaplatin family of compounds in 2005, including PT-112, which demonstrated efficacy against nearly all of the National Cancer Institute’s 60 major human cancer cell lines in preclinical testing and entered Phase I clinical trials in 2014 at the University of Texas M.D. Anderson Cancer Center, Sarah Cannon Research Institute, and University of Colorado Cancer Center for non-small cell lung cancer, gastrointestinal cancers, and recurrent ovarian cancer. These drugs target tumor suppressor genes, inhibit blood supply to tumors, and selectively kill cancer cells with reduced toxicity compared to traditional platinum therapies. Bose held six issued and four pending U.S. patents related to cancer therapeutics and fuel cell catalysts. He was elected a Fellow of the National Academy of Inventors in 2013, served as chairman of the Science Advisory Board of Phosplatin Therapeutics, reviewed for funding agencies and journals, and sat on editorial boards. His work significantly advanced cancer treatment innovation and bolstered the University of Houston’s research enterprise.